VIP (Vasoactive Intestinal Peptide): Research, Mechanisms, and What the Data Show

Key takeaways

• VIP is a 28-amino-acid neuropeptide with broad effects in the gut, immune system, lungs, and brain.
• In intestinal organoid and mouse studies, VIP promoted secretory differentiation, changed progenitor cell behavior, and helped reduce radiation injury.
• Older animal research found VIP reduced signs of experimental arthritis, with lower inflammation and less joint damage.
• VIP also changes activity in the suprachiasmatic nucleus, the brain region tied to circadian rhythm.

What VIP is

Vasoactive Intestinal Peptide, or VIP, is a 28-amino-acid peptide found in many tissues. It is produced by neurons in the enteric nervous system and also appears in the central and peripheral nervous systems and the lungs. It acts through class II G protein-coupled receptors, mainly VPAC1 and VPAC2. That receptor range helps explain why VIP shows up in very different biology, from gut motility to immune control and circadian timing.

VIP was first described as a peptide with strong effects on intestinal blood vessels and smooth muscle. Later work expanded that view. It is now treated as a pleiotropic signaling molecule with anti-inflammatory, bronchodilatory, neuroprotective, and immunomodulatory roles. In the gut, it can relax smooth muscle, increase secretion, and affect epithelial behavior. In the brain, it helps regulate the suprachiasmatic nucleus, which is central to sleep-wake timing.

VIP in the gut

Effects on motility and secretion

VIP has long been linked to intestinal function. In the digestive system, it relaxes smooth muscle, increases water and electrolyte secretion, and can inhibit gastric acid secretion. It also supports pancreatic bicarbonate secretion and affects gallbladder and lower esophageal sphincter tone. These actions fit with its original name and the role it plays in bowel physiology.

The gut is where some of the clearest modern data appear. A 2024 mouse and organoid study found that VIP promotes epithelial differentiation toward a secretory phenotype, and that this effect mainly runs through the p38 MAPK pathway. The same study also found that VIP changed epithelial proliferation and altered the number and proliferative activity of Lgr5-EGFP positive progenitor cells under homeostatic conditions. That matters because Lgr5-positive cells are key intestinal stem and progenitor cells.

Radiation injury and regeneration

The same study looked at injury after irradiation. In jejunal organoids exposed to 6 Gy of irradiation, VIP had stronger effects on progenitor cells, and those changes matched a strong boost in epithelial regeneration. In vivo, mice received 12 Gy of abdominal irradiation and then VIP by intraperitoneal injection. VIP prominently reduced radiation-induced injury in that model. The authors concluded that VIP governs intestinal homeostasis by regulating progenitor cell proliferation and differentiation and helps promote intestinal regeneration.

That finding is important for two reasons. First, it shows VIP is not only a signaling molecule for normal gut function. It also appears to participate in repair after damage. Second, the response depended on cell state. Irradiation made Lgr5-EGFP positive cells more sensitive to VIP-linked changes. That suggests context matters a lot.

VIP and the immune system

Anti-inflammatory patterns in animal studies

VIP is one of the better-known endogenous neuropeptides with anti-inflammatory activity. A long-standing review of its biology described two main immune roles: it helps balance pro-inflammatory and anti-inflammatory signals, and it supports the emergence of regulatory T cells that suppress autoreactive T cell effector responses.

That immune profile shows up in disease models. In a mouse model of collagen-induced arthritis, VIP delayed disease onset, reduced incidence, and lowered severity when given intraperitoneally either daily or on alternate days for two weeks. Histology showed less inflammatory infiltrate, pannus formation, cartilage destruction, and bone erosion. The reported mechanisms included inhibition of T-cell clonal expansion, reduced Th1 cytokines such as interferon-gamma, increased Th2 cytokines such as IL-4, lower type II collagen-specific IgG, lower synovial CD4:CD8 ratio, suppression of inflammatory cytokines like TNF and IL-1, and higher anti-inflammatory mediators like IL-10 and IL-1 receptor antagonist. The study also reported lower MMP-2 gelatinase expression and activity.

Another preclinical study in a mouse model of Crohn’s disease also reported therapeutic effects of VIP. Taken together, the animal data point to a compound that can shift immune tone away from aggressive inflammation. That does not make it a treatment by itself, but it does explain why it remains of interest in autoimmune and inflammatory research.

Immune tolerance and regulatory cells

VIP is also tied to immune tolerance. One review described it as an endogenous agent that helps maintain self-tolerance. Its effects include reducing the balance of pro-inflammatory factors and increasing anti-inflammatory ones. It also supports regulatory T cells with suppressive activity against autoreactive effector cells. This is one of the main themes across VIP literature: it does not act like a single-pathway blocker. It seems to influence immune networks more broadly.

Some summaries of newer research also describe suppression of inflammatory signaling in immune cells through VPAC1 and VPAC2, with lower NF-kB activation and lower output of cytokines such as IL-6, TNF-alpha, and IL-12. They also describe higher IL-10 and TGF-beta1 signaling. Those details fit the broader anti-inflammatory pattern seen in the older animal studies.

VIP in the brain and circadian system

VIP is not only a gut and immune peptide. It also plays a clear role in the brain, especially in the suprachiasmatic nucleus, or SCN. In one study, applying VIP increased the spontaneous firing rate of dorsal SCN neurons during the night. The effect was seen at 1 and 10 micromolar, while 0.1 micromolar did not change firing rate. The response was not just brief. The study reported long-lasting excitation that returned to control levels within 4 to 6 hours after VIP application.

That matters because the SCN is the body’s main circadian clock. A peptide that changes SCN firing can influence how timing signals are processed in the brain. Other summaries of VIP biology describe it as chronobiotic, meaning involved in circadian rhythm regulation. The SCN findings give that label a concrete physiological basis.

VIP in the lungs and cardiovascular system

VIP is also described as a bronchodilator and vasodilator. It relaxes smooth muscle in the airways and blood vessels. Some summaries say it is the primary endogenous bronchodilator and pulmonary vasodilator in the lungs. It is also linked with cardiovascular effects such as coronary vasodilation and changes in heart contractility and rate.

These functions make VIP a wide-ranging signaling peptide rather than a single-purpose molecule. The same peptide can affect blood flow, airway tone, gut secretion, immune balance, and brain rhythm. That broad footprint is part of why VIP remains a research focus across several fields at once.

What the current data can and cannot tell us

The evidence base for VIP is mixed in the way much peptide research is mixed: strong mechanistic signals in cells and animals, but far less direct clinical proof in humans. The research provided here supports several clear points. VIP can alter intestinal epithelial differentiation. It can promote regeneration after experimental radiation injury. It can reduce signs of arthritis in animal models. It can change SCN neuron activity. It has broad anti-inflammatory signaling effects in preclinical work.

What these studies do not do is establish routine clinical use in humans. Dose ranges, delivery methods, and protocols in online product pages are not evidence of efficacy. They are not enough to guide real-world use on their own. The research here is strongest when describing biology, not when making broad claims about outcomes in people.

Why VIP attracts attention in peptide research

VIP stands out because it connects systems that are often studied separately. In the gut, it touches secretion, smooth muscle, stem cells, and repair. In the immune system, it shifts inflammatory signaling and supports tolerance. In the brain, it changes SCN electrical activity. In the lungs and blood vessels, it relaxes smooth muscle and affects tone.

That makes VIP useful as a research tool for asking a simple question with complex answers: what happens when a single endogenous peptide coordinates cell behavior across tissue systems? The current literature suggests the answer depends heavily on dose, route, tissue type, and injury state. In healthy tissue, VIP can shape baseline physiology. In damaged tissue, it may change the repair response. In inflammatory settings, it may push the system toward restraint rather than escalation.

For researchers, that combination is the point. VIP is not a narrow molecule. It is a signaling hub.

FAQ

What is VIP?

VIP stands for vasoactive intestinal peptide. It is a 28-amino-acid neuropeptide found in the gut, brain, lungs, and other tissues. It acts through VPAC1 and VPAC2 receptors and influences secretion, smooth muscle tone, immune activity, and circadian signaling.

What does VIP do in the gut?

VIP relaxes smooth muscle, increases water and electrolyte secretion, and can inhibit gastric acid secretion. In a 2024 organoid and mouse study, it also pushed intestinal epithelial cells toward a secretory phenotype and helped protect against radiation injury.

Is VIP an anti-inflammatory peptide?

Yes, in preclinical research it acts as an anti-inflammatory and immunomodulatory peptide. Animal studies showed reduced arthritis severity, lower inflammatory cytokines, and higher anti-inflammatory signals. Reviews also describe a role in immune tolerance and regulatory T cell activity.

Does VIP affect the brain?

Yes. One study found that VIP increased firing in dorsal suprachiasmatic nucleus neurons during the night, and the effect lasted for hours. That supports its role in circadian rhythm signaling.

What are the main limits of the evidence?

Most of the strongest findings come from cell, organoid, and animal studies. Those results are useful for mechanism, but they do not prove routine human use or define a clinical protocol.